Cargando…
Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations
BACKGROUND: Chagas disease (CD), caused by the parasite Trypanosoma cruzi, is a serious public health concern in Latin America. Nifurtimox and benznidazole (BZ), the only two drugs currently approved for the treatment of CD, have very low efficacies in the chronic phase of the disease and several to...
Autores principales: | Lima, Davi Alvarenga, Gonçalves, Leilane Oliveira, Reis-Cunha, João Luís, Guimarães, Paul Anderson Souza, Ruiz, Jeronimo Conceição, Liarte, Daniel Barbosa, Murta, Silvane Maria Fonseca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204194/ https://www.ncbi.nlm.nih.gov/pubmed/37217925 http://dx.doi.org/10.1186/s13071-023-05775-4 |
Ejemplares similares
-
Molecular characterization of the hexose transporter gene in benznidazole resistant and susceptible populations of Trypanosoma cruzi
por: dos Santos, Paula F, et al.
Publicado: (2012) -
Overexpression of eukaryotic initiation factor 5A (eIF5A) affects susceptibility to benznidazole in Trypanosoma cruzi populations
por: Moreira, Douglas de Souza, et al.
Publicado: (2018) -
Comparative transcriptomic analysis of antimony resistant and susceptible Leishmania infantum lines
por: Andrade, Juvana Moreira, et al.
Publicado: (2020) -
Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain
por: Fonseca, Kátia da Silva, et al.
Publicado: (2021) -
Benznidazole Biotransformation and Multiple Targets in Trypanosoma cruzi Revealed by Metabolomics
por: Trochine, Andrea, et al.
Publicado: (2014)